Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD3480 · 8 trials · 6 indications
| Arm | Type | Description |
|---|---|---|
| 1 | PLACEBO_COMPARATOR | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | ACTIVE_COMPARATOR | Placebo during 5 days, active day 6 |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | - |
| AZD3480 | DRUG | Capsules 5 mg/day (once a day) for 2 weeks |
| Donepezil | DRUG | - |
| Aripiprazole | DRUG | single dose on day 5 |
| Moxifloxacin | DRUG | Capsule(encapsulated), oral, single dose |
| 2-[18F]-F-A85380 | RADIATION | Single dose, IV |
| Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin) | DRUG | Cocktail mix which contains the following: CYP1A2 (Caffeine), CYP2B6 (Bupropion), CYP2C8 (Rosiglitazone), CYP2C19 (Omeprazole), CYP3A4 (Midazolam), UGT1A1 (Bilirubin) single dose of mix |
| Warfarin | DRUG | Warfarin: single dose on day 6 |
Inclusion Criteria: * Confirmed diagnosis of DSM-IV ADHD * Score of equal or more than 2 on at least six of nine items in at least one of the subscales of the Connor´s Adult ADHD Rating Scale (CAARS-INV) * Score of equal or more than 4 (at least moderate severity) on the Clinical Global Impressions...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | SUPN | 1 | PHASE3 | SPN-812 |
AZD3480 is an investigational small molecule being studied for use in psychiatry, specifically for conditions including schizophrenia, attention-deficit/hyperactivity disorder (ADHD), and Alzheimer's disease. It has been evaluated in clinical trials for cognitive improvement in schizophrenia and for the treatment of adult ADHD.
AZD3480 is being developed by AstraZeneca PLC, a biopharmaceutical company traded on the stock exchange under the ticker symbol AZN. The company has sponsored clinical trials of this investigational drug.
AZD3480 is in Phase 2 clinical development. It has completed Phase 2 trials for schizophrenia and ADHD, as well as Phase 1 drug interaction studies. The drug is investigational and has not been approved by regulatory authorities.
AZD3480 has completed several clinical trials, including NCT00528905, a Phase 2 proof-of-concept study in schizophrenia with 400 participants, and NCT00683462, a Phase 2 exploratory trial in adult ADHD with 24 participants. Phase 1 drug interaction studies include NCT00689559 and NCT00689637.
Yes, AZD3480 is also known as TC-1734. In clinical trial NCT00683462, the drug is referred to as AZD3480 (TC-1734), indicating that these names refer to the same investigational compound.